When they offered to test Remdesivir, an investigational drug that has shown promise against some other coronaviruses, “I never even once thought of saying” no “,” said Singh. , specialist in cardiology.
Coronavirus patients around the world are rushing to join the remdesivir studies that have started in hospitals in recent weeks.
The interest has been so great that the National Institutes of Health in the United States is expanding their study, which has almost met its original target of 440 patients. California-based drug maker Gilead Sciences is also rapidly ramping up its own studies.
The story continues under advertising
3 out of 4 American hospitals are already treating coronavirus patients with the worst to come
“I would enlist my family in the blink of an eye” if the need arose, said Dr. Libby Hohmann, who placed Singh and nearly 30 others in the NIH General Mass. Not having COVID-19 approved drugs now is “a little terrifying,” she said.
For most people, the new coronavirus causes mild or moderate symptoms, which can include fever and cough, but sometimes pneumonia requiring hospitalization. The risk of death is greater for the elderly and those with other health conditions.
Remdesivir is administered intravenously. It is designed to interfere with an enzyme that reproduces viral genetic material.
[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]
In animal trials of SARS and MERS, diseases caused by similar coronaviruses, the drug helped prevent infection and reduce the severity of symptoms when given early enough during illness . It is more advanced in testing than many other potential therapies and current studies could lead to regulatory approval.
VIDO-InterVac receives $ 23.3 million from the federal government to fight COVID-19
Gilead has administered remdesivir to more than 1,700 patients on a case-by-case basis, but more people will ultimately be helped if the company studies to prove safety and effectiveness, wrote CEO Dan O’Day in a recent letter. to the public.
“Many people have contacted Gilead to advocate for access to remdesivir on behalf of friends and relatives. I can only imagine what it must be like to feel in this situation, ”he wrote. “We take an ethical and responsible approach.”
In another letter on Saturday, O’Day said the company had 1.5 million doses, which could mean more than 140,000 treatment cycles, depending on the length of treatment. The company is providing the drug free of charge at the moment and has set a target of completing 500,000 courses of treatment by October and more than a million by the end of the year.
Gilead has provided remdesivir for two studies in China that are expected to yield results by the end of the month. He also launched two studies for hospital patients in the United States, Asia, Europe and elsewhere. A critically ill patient tests five to 10 days of treatment. Another, in moderately ill patients, compares these two options to standard care alone.
Canada plans to disinfect and reuse masks during times of shortage, says Tam
“The disease is causing so much anxiety that the patients are very interested” and no one has offered the opportunity to refuse, said Dr. Arun Sanyal, chief of study at Virginia Commonwealth University in Richmond.
The first patient he recruited was a previously healthy, middle-aged man who had an out-of-state visitor a few days before his symptoms started. What started out as a mild illness degenerated into a shortness of breath that required additional oxygen.
At University Medical Hospital Cleveland Medical Center, Dr. Grace McComsey has registered approximately half a dozen patients.
“We are seeing more and more young people, like 30, really sick,” she said.
The NIH study is the most rigorous test. He compares remdesivir to placebo infusions, and neither patients nor doctors know who is receiving what until the end of the study. Besides the United States, it is open in Japan, Korea and Singapore.
Federal government triples COVID-19 research funding
In Chicago, an 89-year-old man was the first attendee at Northwestern Memorial Hospital and “the family was very excited” to see him included, said Dr. Babafemi Taiwo, chief of infectious diseases.
At the University of California, Irvine, Dr. Alpesh Amin has enrolled several patients. All receive standard care even if they end up getting a placebo rather than remdesivir, Amin said.
Boston cardiologist Singh said he was ready to seize this opportunity to advance science, even if he ended up personally missing out. He is now recovering after spending a week in the hospital.
“Some people are freaked out by the word” placebo “, but rigorous testing is necessary to avoid raising false hopes or using something dangerous. Yet it is difficult to confront patients without proven therapy now, said Hohmann.
“The worst part is seeing very young people who are really, really sick,” like a 49-year-old man with three young children in intensive care, she said. “It’s pretty horrible. “
See the link »
© 2020 The Canadian Press